Prospective randomized comparison of effect on coronary endothelial and renal function between febuxostat and benzbromarone in hyperuricemic patients with coronary artery disease: EFEF study

Abstract Background and Aims There are two types of serum uric acid‐lowering agents, the xanthine oxidoreductase (XO) inhibitor and non‐XO inhibitor. We investigated whether febuxostat, XO inhibitor, could produce more favorable effects on coronary endothelial function (CEF) and renal function than...

詳細記述

書誌詳細

出版年:	Health Science Reports
主要な著者:	Masami Nishino, Yasuyuki Egami, Hitoshi Nakamura, Kohei Ukita, Akito Kawamura, Yutaka Matsuhiro, Koji Yasumoto, Masaki Tsuda, Akihiro Tanaka, Naotaka Okamoto, Yasuharu Matsunaga‐Lee, Masamichi Yano, Ryu Shutta, Jun Tanouchi
フォーマット:	論文
言語:	英語
出版事項:	Wiley 2022-03-01
主題:	coronary artery disease endothelial function febuxostat renal function uric acid
オンライン･アクセス:	https://doi.org/10.1002/hsr2.563